Sanofi (NASDAQ:SNY) Shares Sold by Wrapmanager Inc.

Wrapmanager Inc. lowered its stake in Sanofi (NASDAQ:SNY) by 18.3% during the third quarter, Holdings Channel.com reports. The firm owned 6,981 shares of the company’s stock after selling 1,562 shares during the quarter. Wrapmanager Inc.’s holdings in Sanofi were worth $402,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Boston Partners raised its position in Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after purchasing an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after acquiring an additional 246,224 shares during the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Sanofi by 26.5% in the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after acquiring an additional 673,172 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Up 1.1 %

Shares of SNY stock opened at $48.51 on Tuesday. The business’s 50 day moving average is $54.45 and its two-hundred day moving average is $52.22. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a market capitalization of $123.11 billion, a P/E ratio of 24.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the firm earned $2.55 EPS. Equities analysts forecast that Sanofi will post 4.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SNY. Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.